For research use only. Not for therapeutic Use.
Cephalothin（Cat No.:R053346）is a first-generation cephalosporin antibiotic used to treat various bacterial infections. It works by inhibiting bacterial cell wall synthesis, making it effective against Gram-positive organisms like Staphylococcus and Streptococcus. Cephalothin is commonly used in treating respiratory tract infections, skin infections, and urinary tract infections. It is administered via intravenous or intramuscular injection. This antibiotic is less effective against Gram-negative bacteria compared to second- and third-generation cephalosporins. Due to its side effect profile and potential for resistance, cephalothin is typically used when other treatments are not suitable.
| Catalog Number | R053346 |
| CAS Number | 153-61-7 |
| Synonyms | (6R,7R)-3-[(Acetyloxy)methyl]-8-oxo-7-[[2-(2-thienyl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid; 7-(2-Thienylacetamido)cephalosporanic Acid; 7-(Thiophene-2-acetamido)cephalosporin; 7-[2-(2-Thienyl)acetylamido]?cephalosporanic |
| Molecular Formula | C16H16N2O6S2 |
| Purity | ≥95% |
| Target | Beta-lactamase |
| Storage | Store at -20°C |
| IUPAC Name | (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| InChI | InChI=1S/C16H16N2O6S2/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23)/t12-,15-/m1/s1 |
| InChIKey | XIURVHNZVLADCM-IUODEOHRSA-N |
| SMILES | CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC3=CC=CS3)SC1)C(=O)O |
| Reference | </br>1:Cephalothin is not a reliable surrogate marker for oral cephalosporins in susceptibility testing of Enterobacteriaceae causing urinary tract infection. López IA, Montes JC, Álvarez MJ, Mazarrasa CF, Martínez-Martínez L.Diagn Microbiol Infect Dis. 2016 Dec;86(4):412-416. doi: 10.1016/j.diagmicrobio.2016.08.017. Epub 2016 Aug 26. PMID: 27640080 </br>2:Effectiveness of the scheme reimpregnation maintenance schedule vs. ceftazidime/cephalothin in dialysis patients with peritonitis. Carranza-Torres JM, Vargas-Daza ER, Villarreal-Ríos E, Galicia-Rodríguez L, Martínez-González L.Nefrologia. 2016 Jul-Aug;36(4):448-50. doi: 10.1016/j.nefro.2016.02.006. Epub 2016 Mar 19. English, Spanish. No abstract available. PMID: 27006330 Free Article</br>3:Deacylation Mechanism and Kinetics of Acyl-Enzyme Complex of Class C β-Lactamase and Cephalothin. Tripathi R, Nair NN.J Phys Chem B. 2016 Mar 17;120(10):2681-90. doi: 10.1021/acs.jpcb.5b11623. Epub 2016 Mar 8. PMID: 26918257 </br>4:Antibacterial Activity of Alkaloid Fractions from Berberis microphylla G. Forst and Study of Synergism with Ampicillin and Cephalothin. Manosalva L, Mutis A, Urzúa A, Fajardo V, Quiroz A.Molecules. 2016 Jan 11;21(1):76. doi: 10.3390/molecules21010076. PMID: 26760994 Free Article</br>5:Synthesis, characterization and antibacterial activity of a tridentate Schiff base derived from cephalothin and sulfadiazine, and its transition metal complexes. Anacona JR, Noriega N, Camus J.Spectrochim Acta A Mol Biomol Spectrosc. 2015 Feb 25;137:16-22. doi: 10.1016/j.saa.2014.07.091. Epub 2014 Aug 19. PMID: 25194315 </br>6:The use of infrared spectroscopy and artificial neural networks for detection of uropathogenic Escherichia coli strains/’ susceptibility to cephalothin. Lechowicz L, Urbaniak M, Adamus-Białek W, Kaca W.Acta Biochim Pol. 2013;60(4):713-8. PMID: 24432322 Free Article</br>7:Increasing urinary calcium excretion after ceftriaxone and cephalothin therapy in adults: possible association with urolithiasis. Otunctemur A, Ozbek E, Polat EC, Cekmen M, Dursun M, Cakir SS.Urolithiasis. 2014 Apr;42(2):105-8. doi: 10.1007/s00240-013-0627-y. Epub 2013 Dec 6. PMID: 24310104 </br>8:Correlation of cefpodoxime susceptibility with cephalothin and cefuroxime for urinary tract isolates. Bookstaver DA, Bland CM, Woodberry MW, Mansell KB.J Med Microbiol. 2014 Feb;63(Pt 2):218-21. doi: 10.1099/jmm.0.063040-0. Epub 2013 Nov 8. PMID: 24214230 </br>9:Cephalothin susceptibility testing as class representative for oral cephalosporins: is it time to move on? Nguyen HM, Graber CJ.Diagn Microbiol Infect Dis. 2013 Aug;76(4):483-5. doi: 10.1016/j.diagmicrobio.2013.03.022. Epub 2013 May 14. PMID: 23680238 </br>10:A case of cephalothin-associated urolithiasis. Lim IW, Stride PJ, Horvath RL.Clin Pharmacol. 2011;3:1-3. doi: 10.2147/CPAA.S16516. Epub 2011 Feb 28. PMID: 22287851 Free PMC Article |
